Barclays Maintains Overweight on Macrogenics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Macrogenics (NASDAQ:MGNX) but lowers the price target from $9 to $8.
July 31, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Macrogenics but lowers the price target from $9 to $8.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100